Join Growin Stock Community!

Pediatrix medical group, inc.MD.US Overview

US StockHealthcare
(No presentation for MD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MD AI Insights

MD Overall Performance

MD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MD Recent Performance

-1.06%

Pediatrix medical group, inc.

0.05%

Avg of Sector

-0.31%

S&P500

MD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MD Key Information

MD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MD Profile

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

Price of MD

MD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.93
PE Ratio (TTM)
10.39
Forward PE
12.39
PS Ratio (TTM)
0.90
PB Ratio
1.91
Price-to-FCF
6.65
METRIC
VALUE
vs. INDUSTRY
Gross Margin
25.80%
Net Margin
8.64%
Revenue Growth (YoY)
-4.92%
Profit Growth (YoY)
8.66%
3-Year Revenue Growth
-1.32%
3-Year Profit Growth
2.85%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.93
PE Ratio (TTM)
10.39
Forward PE
12.39
PS Ratio (TTM)
0.90
PB Ratio
1.91
Price-to-FCF
6.65
Gross Margin
25.80%
Net Margin
8.64%
Revenue Growth (YoY)
-4.92%
Profit Growth (YoY)
8.66%
3-Year Revenue Growth
-1.32%
3-Year Profit Growth
2.85%

  • When is MD's latest earnings report released?

    The most recent financial report for Pediatrix medical group, inc. (MD) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MD's short-term business performance and financial health. For the latest updates on MD's earnings releases, visit this page regularly.

  • Where does MD fall in the P/E River chart?

    According to historical valuation range analysis, Pediatrix medical group, inc. (MD)'s current price-to-earnings (P/E) ratio is 9.69, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of MD?

    According to the latest financial report, Pediatrix medical group, inc. (MD) reported an Operating Profit of 48.79M with an Operating Margin of 9.88% this period, representing a growth of 28.21% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is MD's revenue growth?

    In the latest financial report, Pediatrix medical group, inc. (MD) announced revenue of 493.77M, with a Year-Over-Year growth rate of -1.71%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does MD have?

    As of the end of the reporting period, Pediatrix medical group, inc. (MD) had total debt of 634.62M, with a debt ratio of 0.28. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MD have?

    At the end of the period, Pediatrix medical group, inc. (MD) held Total Cash and Cash Equivalents of 375.24M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does MD go with three margins increasing?

    In the latest report, Pediatrix medical group, inc. (MD) achieved the “three margins increasing” benchmark, with a gross margin of 25.5%%, operating margin of 9.88%%, and net margin of 6.8%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MD's profit trajectory and future growth potential.

  • Is MD's EPS continuing to grow?

    According to the past four quarterly reports, Pediatrix medical group, inc. (MD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.41. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MD?

    Pediatrix medical group, inc. (MD)'s Free Cash Flow (FCF) for the period is 108.82M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 16.02% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MD?

    The latest valuation data shows Pediatrix medical group, inc. (MD) has a Price-To-Earnings (PE) ratio of 9.69 and a Price/Earnings-To-Growth (PEG) ratio of -0.25. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.